Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOMOPHYLLIN vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing c AMP levels, and antagonizing adenosine receptors. It also has anti-inflammatory and immunomodulatory effects.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Treatment of asthma and reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, prevention of exacerbations in COPD
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
Oral: 200–400 mg every 6 hours; IV: 6 mg/kg loading dose over 30 minutes, then 0.4–0.6 mg/kg/h continuous infusion.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
The terminal elimination half-life of theophylline is approximately 8 hours in healthy non-smoking adults (range 3-12 hours). It is prolonged in patients with hepatic cirrhosis (up to 30 hours), heart failure (up to 30 hours), and in neonates (20-30 hours). Smoking (including marijuana) decreases half-life to 4-5 hours. Half-life is shorter in children (3-5 hours). Clinical context: Due to narrow therapeutic index, half-life variability necessitates therapeutic drug monitoring.
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Primarily hepatic via cytochrome P450 enzymes, mainly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolized to 3-methylxanthine, 1,3-dimethyluric acid, and 1-methyluric acid.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Theophylline is primarily eliminated by hepatic metabolism (>90%), with only about 10-15% excreted unchanged in urine. Renal excretion of the parent drug is minor; however, metabolites are excreted renally. Biliary/fecal excretion accounts for less than 1%.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Theophylline is approximately 40% bound to plasma proteins, primarily albumin. Protein binding is decreased in neonates, patients with hepatic disease, and in the presence of unbound fatty acids.
92-96%, primarily to albumin and alpha-1-acid glycoprotein
The apparent volume of distribution (Vd) of theophylline is approximately 0.45 L/kg (range 0.3-0.7 L/kg). This approximates total body water. Vd is increased in premature infants (0.6-0.8 L/kg) and patients with hepatic disease. Clinical meaning: Vd is used to calculate loading dose.
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Oral immediate-release: 96-100% (rapidly and completely absorbed). Oral sustained-release: 80-100% depending on formulation. Rectal enema: 80-100%. Rectal suppository: 70-90%. IV: 100%.
Oral: 40-50%; Inhalation: 20-30%
No adjustment necessary in renal impairment as theophylline is primarily hepatically metabolized. However, in severe renal failure (Cr Cl <10 m L/min), consider reducing dose by 25%.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
Child-Pugh Class A: reduce dose by 25%; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75% or avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Loading dose: 6 mg/kg IV; maintenance: <1 year: (0.2 x age in weeks) + 5 mg/kg/day divided q4-6h; 1-9 years: 20-24 mg/kg/day divided q4-6h; >9 years: 16 mg/kg/day divided q4-6h.
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Elderly patients >60 years: reduce maintenance dose by 25-50% due to decreased clearance; monitor serum levels closely; target 5-15 mg/L.
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
None. However, close monitoring of serum theophylline levels is required due to narrow therapeutic index.
No FDA black box warning.
Serum levels must be monitored to avoid toxicity (target 5-15 mcg/m L). Use with caution in patients with cardiac disease, seizure disorders, hepatic impairment, and elderly. Drug interactions (e.g., cimetidine, fluoroquinolones, macrolides) can increase levels. Smoking induces metabolism leading to decreased efficacy.
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to theophylline or any component; active seizure disorder; uncontrolled cardiac arrhythmias; peptic ulcer disease (relative).
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may increase central nervous system stimulation. Charcoal-broiled foods and high-protein/low-carbohydrate diets may increase clearance of theophylline, potentially reducing efficacy.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk of minor malformations based on animal data. Second and third trimesters: No evidence of major teratogenicity; risk of fetal tachycardia and irritability due to transplacental passage; avoid high doses near term.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Excreted into breast milk with M/P ratio approximately 0.6-0.9. Infant serum levels may reach therapeutic range at maternal doses >10 mg/kg/day; monitor infant for irritability or insomnia. Generally considered compatible with breastfeeding but use lowest effective dose.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
Second and third trimesters: Increased clearance due to estrogen-induced hepatic metabolism; may require dose increase by 20-40% to maintain therapeutic levels. Postpartum: Clearance returns to prepregnancy levels within 2-4 weeks; reduce dose accordingly.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
SOMOPHYLLIN (theophylline) is a narrow therapeutic index drug; monitor serum levels (therapeutic range 5-15 μg/m L for asthma). Use with caution in patients with hepatic impairment, congestive heart failure, or elderly due to reduced clearance. Cigarette smoking and charcoal-broiled foods increase clearance, requiring dose adjustment. Concurrent use with cimetidine, fluoroquinolones, or macrolides can increase levels and toxicity.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid smoking and charcoal-grilled foods as they can affect drug levels.,Avoid caffeine-containing beverages and foods (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: persistent nausea, vomiting, insomnia, palpitations, or seizures.,Missed dose: take as soon as remembered unless close to next dose; do not double dose.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOMOPHYLLIN vs AEROLATE III, answered by our medical review team.
SOMOPHYLLIN is a Bronchodilator that works by Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing c AMP levels, and antagonizing adenosine receptors. It also has anti-inflammatory and immunomodulatory effects.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOMOPHYLLIN and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOMOPHYLLIN is: Oral: 200–400 mg every 6 hours; IV: 6 mg/kg loading dose over 30 minutes, then 0.4–0.6 mg/kg/h continuous infusion.. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOMOPHYLLIN and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOMOPHYLLIN is classified as Category C. FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk of minor malformations based on animal data. Second and third trimesters: No evidence of major. AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.